1. Home
  2. RYTM vs PLXS Comparison

RYTM vs PLXS Comparison

Compare RYTM & PLXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • PLXS
  • Stock Information
  • Founded
  • RYTM 2008
  • PLXS 1979
  • Country
  • RYTM United States
  • PLXS United States
  • Employees
  • RYTM N/A
  • PLXS N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • PLXS Electrical Products
  • Sector
  • RYTM Health Care
  • PLXS Technology
  • Exchange
  • RYTM Nasdaq
  • PLXS Nasdaq
  • Market Cap
  • RYTM 4.3B
  • PLXS 3.6B
  • IPO Year
  • RYTM 2017
  • PLXS 1986
  • Fundamental
  • Price
  • RYTM $65.25
  • PLXS $136.76
  • Analyst Decision
  • RYTM Strong Buy
  • PLXS Buy
  • Analyst Count
  • RYTM 12
  • PLXS 4
  • Target Price
  • RYTM $77.50
  • PLXS $157.33
  • AVG Volume (30 Days)
  • RYTM 585.3K
  • PLXS 160.2K
  • Earning Date
  • RYTM 08-05-2025
  • PLXS 07-23-2025
  • Dividend Yield
  • RYTM N/A
  • PLXS N/A
  • EPS Growth
  • RYTM N/A
  • PLXS 41.85
  • EPS
  • RYTM N/A
  • PLXS 5.14
  • Revenue
  • RYTM $136,863,000.00
  • PLXS $3,967,612,000.00
  • Revenue This Year
  • RYTM $37.56
  • PLXS $4.62
  • Revenue Next Year
  • RYTM $74.99
  • PLXS $9.00
  • P/E Ratio
  • RYTM N/A
  • PLXS $26.60
  • Revenue Growth
  • RYTM 48.88
  • PLXS N/A
  • 52 Week Low
  • RYTM $40.46
  • PLXS $101.64
  • 52 Week High
  • RYTM $69.89
  • PLXS $172.89
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 53.08
  • PLXS 62.02
  • Support Level
  • RYTM $60.80
  • PLXS $134.03
  • Resistance Level
  • RYTM $64.00
  • PLXS $137.90
  • Average True Range (ATR)
  • RYTM 1.96
  • PLXS 2.65
  • MACD
  • RYTM -0.13
  • PLXS 0.26
  • Stochastic Oscillator
  • RYTM 44.48
  • PLXS 80.05

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About PLXS Plexus Corp.

Plexus Corp is a U.S based Electronic Manufacturing Services company that provides a range of services, from conceptualization and design to fulfilling orders and providing sustaining solutions, such as replenishment and refurbishment. The company's segments comprise AMER, APAC,ge and EMEA.

Share on Social Networks: